KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
about
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastasesDUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9.Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients.From genotype to functional phenotype: unraveling the metabolomic features of colorectal cancer.Review of histopathological and molecular prognostic features in colorectal cancerKRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.Identification of candidate driver genes in common focal chromosomal aberrations of microsatellite stable colorectal cancerPyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNABRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.Heterogeneity of KRAS Mutation Status in Rectal CancerKRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancerInhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathwayHigh Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.KRAS and BRAF: drug targets and predictive biomarkers.Role of ancillary studies in fine-needle aspiration from selected tumors.Colorectal cancer and RASSF family--a special emphasis on RASSF1A.Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.New and potential clinical applications of KRAS as a cancer biomarker.Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites.Pragmatic issues in biomarker evaluation for targeted therapies in cancer.In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics.Hypericum androsaemum water extract inhibits proliferation in human colorectal cancer cells through effects on MAP kinases and PI3K/Akt pathway.What makes oncogenes mutually exclusive?Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy.KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.Salvia fruticosa, Salvia officinalis, and rosmarinic acid induce apoptosis and inhibit proliferation of human colorectal cell lines: the role in MAPK/ERK pathway.BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status.Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer.
P2860
Q28088489-85F62FA1-AEEA-4812-8D86-DFE5AA35E80CQ31813071-055BFFAC-1094-4CC6-A00E-8F31F793E469Q33832433-DB1B9E48-C174-499A-97DF-4939707E8194Q34013823-D349C45C-3CCF-43DC-8A78-C7BF2627B77BQ34347646-D94143C4-FB48-4905-AC2D-921566E05F8AQ34657323-5E7AD2D1-39CD-4A3A-A4C4-90B96EF1DF6AQ34727184-9C3646F5-FFFA-491C-966C-D251929D3C17Q35075615-9F13D45C-17CA-4131-AB70-4A8A66496936Q35125613-0B3E6AD1-75FA-4A1A-9009-64EB29824B35Q35652713-8A1A7B24-7052-486D-B549-C3A8878214DBQ35810461-AE61F458-83C5-433E-9A98-87052EA9A5A4Q35962621-4EA9E4BF-8AF1-4136-BCC6-27C8DADB64FFQ35985611-8CE425B4-D75E-49B2-A237-07E3419FC6A1Q37023905-05A331FC-CAB0-4072-AD8F-E70F1ACB8C40Q37148431-32055E85-3D19-40B4-9773-B671036B38B1Q37534619-1EDD49B0-E7B6-41C3-A3A2-348AF0CC3367Q37815135-44F7FFF7-00A4-4DD1-BC98-B828BA5C326CQ37951872-6736C8DF-94BE-4093-A0C5-25A3D5F97607Q38021701-DD2550D4-762B-4E6F-A81A-10290EF7538DQ38052918-61CF8989-E6F1-4875-88F3-3B6D11D096E5Q38089885-E54F9969-8912-44D6-A61D-1B3180FC6E1CQ38183348-A01E96DB-A52C-4674-A2C1-4FE4FC7EC6BEQ38271031-5FAFF30D-BC44-4937-91CE-8C8F6501C7D8Q38853649-E825D1E4-FDD2-4E87-819C-83F46BE2C504Q38990791-D0814603-B71F-455C-AD28-219998C5D5B8Q39346470-4351D099-2F03-45EA-87BE-FAE9497022E9Q39602248-993D5E85-D8E2-44B6-953A-BF6EF1ABC207Q39603379-9DE8C2CC-063F-49CF-8FCC-592A20B7EC94Q39642103-6CC800A0-6332-423A-94A5-ECEC470A7046Q39786082-4A315694-7907-451D-AF2D-EC0A9531F1F8Q40031893-969430C4-36E9-4E8A-BFAE-0DCD074CFABBQ42947711-F51B896D-D9A9-4A73-86A4-0BF17F37F0EDQ47586172-7E8AAED6-97E7-4E02-9FA2-D32B92EE25BDQ51552580-01B613DA-DBD2-40EC-A119-6B96B78A87B3Q51649034-7439D72B-1F41-4D07-9984-75C49B081088
P2860
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
description
article
@en
im September 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2006
@uk
name
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
@en
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
@nl
type
label
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
@en
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
@nl
prefLabel
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
@en
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
@nl
P2093
P2860
P50
P356
P1433
P1476
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1209758
P407
P50
P577
2006-09-04T00:00:00Z